Drug – bio-affecting and body treating compositions – Nonspecific immunoeffector – per se ; or nonspecific... – Synthetic or structurally-modified peptidoglycan or...
Patent
1995-02-24
1998-08-25
Smith, Lynette F.
Drug, bio-affecting and body treating compositions
Nonspecific immunoeffector, per se ; or nonspecific...
Synthetic or structurally-modified peptidoglycan or...
424 9371, 4241841, A01N 6300, A61K 3900, A61K 3938, A61K 4500
Patent
active
057980900
ABSTRACT:
DTH-Effector cells are primed with carbohydrate antigens and used to enhance the cellular immune response. Tumors have been inhibited by DTH-Effector cells primed with epiglycanin and with synthetic T and Tn antigens. Either the DTH-Effector cells, or these tumor-associated carbohydrate antigens directly, may be used for tumor prophylaxis and therapy.
REFERENCES:
patent: 4180627 (1979-12-01), Klesius et al.
patent: 4690915 (1987-09-01), Rosenberg
patent: 4971795 (1990-11-01), Longenecker et al.
Springer, et al, 1984, "T and Tn General . . . " Science 224: 1198-1206.
Havelle et al, J. Immunol, 137(5), 1448-54, 1986.
Goldstein et al, J. Exp. Med., 162, pp. 1381-1386, (1985).
Ertl, Cell. Immnunol, 62, 38-49, (1981).
Benjamini et al; Chapter 15 in Basic and Clinical Immunology, Shtes et al eds, 1984 (5.sup.th Edition), Los Altos, CA.
Lefford, Immunology, 41, 635, (1980).
Chemical Abstract, 78, 27836z (for Cooper, Scand. J. Immunol, 1(3), 237-45.
Klein, ed., Immunology: The Science of Self-Nonself Discrimination 465 (1982).
Goldstein, et al., J. Exp. Med., 162:1381 (1985).
Myrvik, et al., Fundamentals of Immunology 134-41 (1985).
Moreno, "Carbohydrates as Immunogens and Tolerogens: Antibody versus Cell-Mediated Immune Responses", in Towards Better Carbohydrates Vaccines, Chapter 19 (1987) at pp. 263, 267.
Henningsson et al., Induction of Immunity to a Mammary Adenocarcinoma using Purified shed Cancer Antigen and Synthetic Carbohydrates, Journal of Leukocyte Biology, vol. 38, abstract No. 70, Jul. 1985.
Bianchi, et al, 1981 "Clones of T Cells Mediate Antigen-Specific . . . " Nature 290: 62-63.
Leung, et al, 1980, "Specificity, Ly Phenotype and H-2 . . . " J. Exp. Med. 151: 815-826.
Greene, et al, 1984, "Delayed Hypersensitivity" In Fundamental Immunology, W.E. Paul, Ed. pp. 685-696.
Codington, JF et al., "Further Studies on the Relationship Between Large Glycoprotein Molecules and Allotransplantability in the TA3 Tumor of the Mouse: Studies on Segregating TA3-Ha Hybrids", J. Natl. Cancer Inst. 6(4):811-818 (Apr. 1978).
Codington, JF et al., "Cell Surface Characteristics of an Allotransplantable TA3 Ascites Subline Resulting from a Process of Immunoselection", Cancer Research 43:4373-4381 (Sep. 1983).
Friberg, S et al., "Comparison of an Immunoresistant and an Immunosusceptible Ascites Subline From Murine Tumor TA3. I. Transplantability, Morphology, and Some Physiochemical Characteristics", J. Nat. Cancer Inst. 48: 1463-1476 (1972).
Bretscher, PA, "In vitro Induction of delayed-type hypersensitivity", Eur. J. Immunol. 9:311-316 (1979).
Henningsson Carina
Longenecker B. Michael
Biomira, Inc.
Cooper Iver P.
Smith Lynette F.
LandOfFree
Enhancement of the cellular immune response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of the cellular immune response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of the cellular immune response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-34443